Literature DB >> 23797307

Spondyloarthritis: Is it time to replace BASDAI with ASDAS?

Pedro Machado1, Robert Landewé.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23797307     DOI： 10.1038/nrrheum.2013.93

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  Patient-acceptable symptom state as an outcome measure in the daily care of patients with ankylosing spondylitis.

Authors:  Carlos Rodríguez-Lozano; María-Ángeles Gantes; Beatriz González; José A Hernández-Beriain; Antonio Naranjo; Vanesa Hernández; Juan C Quevedo-Abeledo; M José Falcón; Sergio Machín; Miguel A Descalzo
Journal:  J Rheumatol       Date:  2012-06-01       Impact factor: 4.666

Review 2.  How to measure disease activity in axial spondyloarthritis?

Authors:  Pedro Machado; Désirée van der Heijde
Journal:  Curr Opin Rheumatol       Date:  2011-07       Impact factor: 5.006

3.  Evaluation and stability of the Patient Acceptable Symptom State (PASS) over time in patients with ankylosing spondylitis.

Authors:  G Wariaghli; F Allali; Z Idrissi; K Berrada; I Hmamouchi; R Abouqal; N Hajjaj-Hassouni
Journal:  Clin Exp Rheumatol       Date:  2012-03-07       Impact factor: 4.473

4.  ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.

Authors:  Susanne Juhl Pedersen; Inge Juul Sørensen; Patrick Garnero; Julia Sidenius Johansen; Ole Rintek Madsen; Niels Tvede; Michael Sejer Hansen; Gorm Thamsborg; Lis Smedegaard Andersen; Ole Majgaard; Anne Gitte Loft; Jon Erlendsson; Karsten Asmussen; Anne Grethe Jurik; Jakob Møller; Maria Hasselquist; Dorrit Mikkelsen; Thomas Skjødt; Robert Lambert; Annette Hansen; Mikkel Østergaard
Journal:  Ann Rheum Dis       Date:  2011-05-08       Impact factor: 19.103

5.  Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.

Authors:  Karen M Fagerli; Elisabeth Lie; Désirée van der Heijde; Marte S Heiberg; Cecilie Kaufmann; Erik Rødevand; Knut Mikkelsen; Synøve Kalstad; Tore K Kvien
Journal:  Rheumatology (Oxford)       Date:  2012-04-11       Impact factor: 7.580

6.  Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.

Authors:  Pedro Machado; Robert Landewé; Elisabeth Lie; Tore K Kvien; Jürgen Braun; Daniel Baker; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-11-10       Impact factor: 19.103

7.  Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients.

Authors:  Marie Godfrin-Valnet; Clément Prati; Marc Puyraveau; Eric Toussirot; Hélène Letho-Gyselink; Daniel Wendling
Journal:  Joint Bone Spine       Date:  2013-03-01       Impact factor: 4.929

8.  MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.

Authors:  Pedro Machado; Robert B M Landewé; Jürgen Braun; Xenofon Baraliakos; Kay-Geert A Hermann; Benjamin Hsu; Daniel Baker; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2012-08-21       Impact factor: 19.103

9.  Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Authors:  Suzanne Arends; Elisabeth Brouwer; Eveline van der Veer; Henk Groen; Martha K Leijsma; Pieternella M Houtman; Tim L Th A Jansen; Cees G M Kallenberg; Anneke Spoorenberg
Journal:  Arthritis Res Ther       Date:  2011-06-20       Impact factor: 5.156
  9 in total
  9 in total

1.  Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study).

Authors:  Agustí Sellas I Fernandez; Xavier Juanola Roura; Alberto Alonso Ruiz; José Rosas; Julio Medina Luezas; Eduardo Collantes Estevez; Miguel Ángel Abad Hernández; Virginia Carrasco Benitez; Cesar Fisac
Journal:  Rheumatol Int       Date:  2017-09-16       Impact factor: 2.631

Review 2.  Treat to Target in Axial Spondyloarthritis: What Are the Issues?

Authors:  Abhijeet Danve; Atul Deodhar
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

Review 3.  Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis.

Authors:  Rachael Stovall; Irene E van der Horst-Bruinsma; Shao-Hsien Liu; Tamara Rusman; Lianne S Gensler
Journal:  Nat Rev Rheumatol       Date:  2022-09-15       Impact factor: 32.286

4.  Performance characteristics of the simplified version of ankylosing spondylitis disease activity score (SASDAS).

Authors:  Dilek Solmaz; Tulay Yildirim; Okan Avci; Nazmiye Tomas; Servet Akar
Journal:  Clin Rheumatol       Date:  2015-12-16       Impact factor: 2.980

Review 5.  Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses.

Authors:  Silvia Menegatti; Elisabetta Bianchi; Lars Rogge
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

6.  Measuring quality of life of patients with axial spondyloarthritis for economic evaluation.

Authors:  Monica Hernandez Alava; Allan Wailoo; Georgios Chrysanthou; Filipe Barcelos; Floris A van Gaalen; Helena Santos; Karen Minde Fagerli; Laura Gago; Maria Margarida Cunha; Marleen van de Sande; Maura C Couto; Miguel Bernardes; Roberta Ramonda; Sofia Exarchou; Pedro D Carvalho; Desirée van der Heijde; Pedro M Machado
Journal:  RMD Open       Date:  2022-02

7.  Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France.

Authors:  Maxime Dougados; Julien Lucas; Emilie Desfleurs; Cédric Lukas; Alain Saraux; Anne Tournadre; Adeline Ruyssen-Witrand; Daniel Wendling; Philippe Goupille; Pascal Claudepierre
Journal:  RMD Open       Date:  2022-03

Review 8.  Meta-Analysis of Changes in the Number and Proportion of Regulatory T Cells in Patients with Ankylosing Spondylitis.

Authors:  Ming Li; Xueping Zhou; Lingling Zhou; Zhichao Yu; Ling Fu; Pei Yang
Journal:  Biomed Res Int       Date:  2020-02-19       Impact factor: 3.411

9.  Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI.

Authors:  Jose Marona; Alexandre Sepriano; Santiago Rodrigues-Manica; Fernando Pimentel-Santos; Ana Filipa Mourão; Nélia Gouveia; Jaime Cunha Branco; Helena Santos; Elsa Vieira-Sousa; Filipe Vinagre; João Tavares-Costa; João Rovisco; Miguel Bernardes; Nathalie Madeira; Rita Cruz-Machado; Raquel Roque; Joana Leite Silva; Mary Lucy Marques; Raquel Miriam Ferreira; Sofia Ramiro
Journal:  RMD Open       Date:  2020-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.